 The children will be followed for 5 years in the study. Primary endpoint is proportion of subjects diagnosed with type 1 diabetes in each treatment arm. Secondary endpoints are 1 safety, 2 change in metabolic status from normal to impaired glucose metabolism in the group of children with normal glucose metabolism at baseline screening. 